Drugs / Rilvegostomig
Trials 35
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06366451 | May 2024 → Mar 2026 | head and neck squamous cell carcinoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 0 | NCT04541108 | Jul 2021 → Dec 2031 expected | cancer | Presage Biosciences | Active not recruiting | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT07161414 | Nov 2025 → Jul 2027 expected | cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT04686305 | Mar 2021 → Jun 2027 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT04612751 | Feb 2021 → May 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03819465 | Dec 2018 → May 2023 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06996782 | Nov 2025 → Feb 2029 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07115043 | Jul 2025 → Oct 2029 expected | cutaneous neuroendocrine carcinoma, gastroesophageal cancer, head and neck squamous cell carcinoma, melanoma +5 | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06005493 | Jul 2023 → Mar 2029 expected | esophageal adenocarcinoma, gastric cancer, gastroesophageal cancer, pancreatic ductal adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05123482 | Oct 2021 → Sep 2027 expected | biliary tract cancer, breast carcinoma, endometrial cancer, non-small cell squamous lung carcinoma +1 | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04995523 | Sep 2021 → Aug 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT07128290 | Oct 2025 → Apr 2029 expected | intrahepatic cholangiocarcinoma | Federation Francophone de Cancerologie Digestive | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07098338 | Aug 2025 → Apr 2029 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT07069712 | Jul 2025 → Nov 2027 expected | gastroesophageal adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT06630130 | Jan 2025 → Oct 2028 expected | gastric cancer | Jeeyun Lee | Recruiting | No outcome recorded |
| Phase 2 | NCT06569225 | Dec 2024 → Dec 2027 expected | cholangiocarcinoma | University Health Network, Toronto | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05414032 | Jul 2023 → Sep 2027 expected | head and neck squamous cell carcinoma | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 2 | NCT05775159 | Apr 2023 → Oct 2026 expected | biliary tract cancer, hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05702229 | Jan 2023 → Nov 2027 expected | gastric cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT05061550 | Apr 2022 → May 2030 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT03741426 | Jul 2020 → Dec 2027 expected | renal cell carcinoma | CCTU- Cancer Theme | Recruiting | No outcome recorded |
| Phase 2 | NCT04379596 | Jun 2020 → Jun 2027 expected | gastric cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT01042379 | Mar 2010 → Dec 2030 expected | HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT07431281 | Feb 2026 → Aug 2029 expected | esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07221253 | Dec 2025 → Jul 2029 expected | biliary tract cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06921785 | May 2025 → Mar 2030 expected | hepatocellular carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06868277 | Apr 2025 → Jan 2030 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06989112 | Mar 2025 → Jan 2029 expected | endometrial cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06764875 | Mar 2025 → Apr 2029 expected | gastroesophageal junction adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06627647 | Nov 2024 → Nov 2030 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06692738 | Nov 2024 → Jul 2030 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06564844 | Oct 2024 → Jul 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06467357 | Aug 2024 → Jun 2028 expected | biliary tract cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06357533 | Apr 2024 → Dec 2029 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06109779 | Dec 2023 → Jan 2029 expected | biliary tract cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05489211 Background | Sep 2022 → Oct 2027 expected | biliary tract cancer, castration-resistant prostate carcinoma, colorectal cancer, endometrial cancer +3 | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rilvegostomig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06467357 ↗ |
| Known as | AZD2936 | “AZD8205 and AZD2936 (Rilvegostomig)” NCT05123482 ↗6“Rilvegostomig (AZD2936)” NCT06692738 ↗ |
| Action | Inhibit | “In the preclinical studies, dual blockade of TIGIT and PD 1 by AZD2936 enhanced human T cell function and promoted antitumor immune responses.” NCT05414032 ↗ |
| Modality | Other / unclassified | “Rilvegostomig is a bispecific antibody” NCT05123482 ↗ |
| Route | Intravenous | “Rilvegostomig: 750mg IV Q3W” NCT01042379 ↗ |
| Target | TIGIT | “Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1” NCT05123482 ↗ |